title: Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging.
abstract: It is proposed that chronic moderate hyperhomocysteinemia has a causal role in a number of common diseases of late life, including occlusive vascular disease, cognitive decline, senile osteoporosis and presbyopia. These diseases are seen as clinical counterparts of the main manifestations of homocystinuria (vascular occlusions of arteries and veins, mental retardation, osteoporosis and ectopia lentis, respectively) that develop only after many years of exposure to moderately elevated homocysteine (Hcy) levels. The multisystem toxicity of Hcy is attributed to its spontaneous chemical reaction with many biologically important molecules, primarily proteins. The formation of these Hcy-adducts is dependent on time and Hcy concentration and leads to loss or diminution of function of the derivatized molecules. Irreversible homocysteinylation of long-lived proteins should lead to cumulative damage and progressive clinical manifestations. Fibrillin 1 is seen as the paradigm of extracellular connective tissue proteins that are specially susceptible to Hcy (and presumably Hcy thiolactone) attack. The prominent presence of epidermal growth factor (EGF)-like domains in fibrillin and in many other extracellular proteins of the coagulation, anticoagulation, and lipoprotein transport pathways, all of which malfunction in hyperhomocysteinemia, suggests that EGF-like domains may be preferential sites of homocysteinylation.
authors.affiliation: Schools of Medicine, Dentistry and Health Related Professions, Department of Nutrition Sciences, University of Alabama at Birmingham, 35294-3360, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Krumdieck
authors.forename: C W
authors.initials: CW
authors.lastname: Prince
mesh_terms: D000375:Aging / Q000378:metabolism*; D000818:Animals; D002908:Chronic Disease; D003238:Connective Tissue / Q000187:drug effects / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000187:drug effects; D006710:Homocysteine / Q000009:adverse effects*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications*
chemical_list: D006710:Homocysteine; D004815:Epidermal Growth Factor